Results 21 to 30 of about 23,835 (226)

Herpes Zoster Vaccines

The Journal of Infectious Diseases, 2018
Immunization for herpes zoster (HZ) aims to reverse the decline in cell-mediated immunity to varicella zoster virus that occurs with advancing age or immunocompromise. There are 2 vaccines available, one live attenuated (Zoster vaccine, live attenuated [ZVL]) and, recently, a recombinant subunit vaccine (HZ/su).The literature relevant to the two HZ ...
Anthony L, Cunningham, Myron J, Levin
openaire   +2 more sources

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination [PDF]

Open Forum Infectious Diseases, 2022
Abstract Background The 2-dose recombinant zoster vaccine (RZV) series is recommended for prevention of herpes zoster (HZ) in adults aged ≥50 years, but data are limited on the impact of concomitant administration with other vaccines on subsequent HZ risk.
Katia J Bruxvoort, Lei Qian, Jun Wu, Ana Florea, Bradley Ackerson, Lina S Sy, Leticia Vega Daily, Harpreet Takhar, Hung Fu Tseng   +8 more
openaire   +2 more sources

Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence

BMC Medicine, 2018
de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults.
Chester B. Good, Natasha Parekh, Inmaculada Hernandez   +2 more
doaj   +1 more source

Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine

Human Vaccines & Immunotherapeutics, 2020
Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination for eligible adults
John Litt, Robert Booy, Debra Bourke, Dominic E. Dwyer, Alan Leeb, Philip McCloud, Alicia N. Stein, Michael Woodward, Anthony L. Cunningham   +8 more
doaj   +1 more source

Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods

Vaccines, 2023
Previous studies have shown that the herpes zoster subunit vaccine Shingrix™ performs well in clinical trials. However, the key ingredient in its adjuvant, QS21, is extracted from rare plants in South America, so vaccine production is limited.
Kangyang Lin, Han Cao, Ning Luan, Yunfei Wang, Jingping Hu, Cunbao Liu   +5 more
doaj   +1 more source

Clinical features of varicella-zoster virus infection [PDF]

, 2018
Varicella-zoster virus (VZV) is a pathogenic human herpes virus that causes varicella (chickenpox) as a primary infection, following which it becomes latent in peripheral ganglia.
Gershon, Anne A., Kennedy, Peter G.E.
core   +1 more source

Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation. [PDF]

, 2012
In pediatric patients with malignancy and those receiving hematopoietic stem cell transplants, bacterial and fungal infections have been the focus of fever and neutropenia episodes for decades.
Alexander, Sarah, Dvorak, Christopher C, Fisher, Brian T, Sung, Lillian, Zaoutis, Theoklis E, Zerr, Danielle M   +5 more
core   +1 more source

Vacunación frente al virus del herpes zóster

Atención Primaria, 2023
Resumen: Objetivo: Revisar las últimas evidencias publicadas respecto a la vacuna utilizada en nuestro país frente al virus del herpes zóster, desglosadas por eficacia, eficiencia, efectividad y seguridad vacunal.
José Javier Gómez Marco, Susana Martín Martín, Pablo Aldaz Herce, Ana Pilar Javierre Miranda, Coro Sánchez Hernández   +4 more
doaj   +1 more source

Varicella paediatric hospitalisations in Belgium : a 1-year national survey [PDF]

, 2016
Background: Varicella universal vaccination (UV) has been implemented in many countries for several years. Nevertheless, varicella UV remains debated in Europe and few data are available on the real burden of infection.
Belgian Group for Varicella, the, Blumental, Sophie, Lepage, Philippe, Sabbe, Martine, Schelstraete, Petra   +4 more
core   +2 more sources

Has VZV epidemiology changed in Italy? Results of a seroprevalence study [PDF]

, 2017
The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era.
Amodio E., Angelillo I., Bagordo F., Baldo V., Baldovin T., Bandettini R., Bassetti D., Bassi C., Bella A., Bernardini S., Binda S., Bonanni P., Bordonaro P., Brignole G., Cacello E., Caligiuri P., Casalino P., Castiglia P., Cia M., Cicerchia E., Clerico L., Cracchiolo M., D'Agaro P., De Donno A., Del Manso M., Devoti G., Di Giuseppe G., Ditommaso S., Fazii P., Gabutti G., Gallo T., Gamper A., Giandomenico A. M., Giraldi C., Grasso G., Greco F., Guerra G., Guido M., Idolo A., Kuhdari P., Lupi S., Maglione F., Manchia P., Megha M., Pagani E., Passamonti B., Pellegrinelli L., Pelliccioni A. R., Perrone M., Peruzzi M., Piana A., Primache V., Renzoni C., Resciniti C., Romano P., Rossi P., Rota M. C., Sammarco M. L., Schettini S., Schippa S., Sciuto V., Segat L., Stefanati A., Sticchi L., Tiscione E., Trucchi C., Tumolo M. R., Vallerini M., Vargiu P., Vitale F., Zizza A., Zotti C.   +71 more
core   +1 more source